your not an ex director with too much time on their hands are you? ha
CBIO's woes can all be laid down to one factor - the management it has had in the past, because there is a drug here. There has been enough cash piled into CBIO to be where we needed - However along the way the company was set back years at a time by mismanagement,unnecessary cash burn, poor leadership and decision making. You only need an understanding of what the capital markets thought of previous management (excluding overseas directors)
The new management have walked in with nothing, and I would expect the ex management are not chivalrous enough to offer any lead information they have for the benefit of the company. The current management are running blind - they need to grab the bull by the horns and make this $10million at bank work (hang on- wasnt there 12-13million raised in the last capital raise?? - (wonder where the difference went?? hmmm)
If cbio can get an intravenous trial away for lupus with an increased take up of the drug in the bloodstream - and supporting data shows inflammation markers supportive of the previous RA trial IL-6 etc ..results showing clear benefit.. then deals will be back on the table.. The scientific team and management need to plan this one meticulously
CBZ Price at posting:
8.1¢ Sentiment: None Disclosure: Held
